AstraZeneca rocked by shareholder revolt over executive pay

More than 37% of shareholders vote against or abstain on vote including £9.4m pay package for pharmaceutical firm’s bossAstraZeneca has been rocked by one of the biggest shareholder revolts over executive pay this year, after more than a third of investors failed to back the pharmaceutical company’s remuneration report. More than 37% of shareholders voted against or abstained at the company’s annual shareholder meeting in London on Friday in the second rebuke by investors